| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced stage melanoma therapies: Detailing the present and exploring the future
|
Luther, Chelsea
|
|
2019
|
133 |
C |
p. 99-111
|
artikel
|
| 2 |
A systematic review examining clinical markers and biomarkers of analgesic response to radiotherapy for cancer-induced bone pain
|
Gardner, Kirstyn
|
|
2019
|
133 |
C |
p. 33-44
|
artikel
|
| 3 |
Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review
|
Jelicic, Jelena
|
|
2019
|
133 |
C |
p. 1-16
|
artikel
|
| 4 |
Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide—A systematic review and meta-analysis
|
Yu, Xiaotong
|
|
2019
|
133 |
C |
p. 120-128
|
artikel
|
| 5 |
Clinical implications of measurable residual disease in AML: Review of current evidence
|
Moors, Ine
|
|
2019
|
133 |
C |
p. 142-148
|
artikel
|
| 6 |
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life
|
Morganti, Stefania
|
|
2019
|
133 |
C |
p. 171-182
|
artikel
|
| 7 |
Congenital neutropenia and primary immunodeficiency diseases
|
Spoor, Jonathan
|
|
2019
|
133 |
C |
p. 149-162
|
artikel
|
| 8 |
Corrigendum to “Bartholin gland cancer” [Crit. Rev. Oncol./Hematol. 117 (September) (2017) 1–11]
|
Di Donato, Violante
|
|
2019
|
133 |
C |
p. 84
|
artikel
|
| 9 |
Editorial Board
|
|
|
2019
|
133 |
C |
p. IFC
|
artikel
|
| 10 |
Erratum to “Lipid metabolism and lung cancer” [Crit. Rev. Oncol. Hematol. 112, April (2017), 31–40]
|
Salvador, María Merino
|
|
2019
|
133 |
C |
p. 45
|
artikel
|
| 11 |
Immunotherapy in advanced gastric cancer, is it the future?
|
Coutzac, C.
|
|
2019
|
133 |
C |
p. 25-32
|
artikel
|
| 12 |
Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors
|
Pluimakers, V.G.
|
|
2019
|
133 |
C |
p. 129-141
|
artikel
|
| 13 |
Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis
|
Tang, Yaqiong
|
|
2019
|
133 |
C |
p. 74-83
|
artikel
|
| 14 |
RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment
|
van Dam, Peter A.
|
|
2019
|
133 |
C |
p. 85-91
|
artikel
|
| 15 |
Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant
|
Fozza, Claudio
|
|
2019
|
133 |
C |
p. 112-119
|
artikel
|
| 16 |
Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review
|
Belgioia, Liliana
|
|
2019
|
133 |
C |
p. 163-170
|
artikel
|
| 17 |
“Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria
|
Lombardi, P.
|
|
2019
|
133 |
C |
p. 17-24
|
artikel
|
| 18 |
Squamous cell carcinoma arising from mature cystic teratoma of the ovary: A challenging question for gynecologic oncologists
|
Gadducci, Angiolo
|
|
2019
|
133 |
C |
p. 92-98
|
artikel
|
| 19 |
Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data
|
Chartron, Elodie
|
|
2019
|
133 |
C |
p. 58-73
|
artikel
|
| 20 |
The potential therapeutic effects of creatine supplementation on body composition and muscle function in cancer
|
Fairman, C.M.
|
|
2019
|
133 |
C |
p. 46-57
|
artikel
|
Tijdschrift beschrijving